Résultats de recherche pour : novodiag

Mobidiag Ltd. today announces that it has signed an agreement with XboXLab for the distribution of its molecular diagnostic products Amplidiag^® and Novodiag^® in Norway.

We are very pleased to expand our distribution network and be able to provide Norwegian clinical laboratories with our innovative molecular diagnostic solutions.

For more information, please contact :
Henning Jansen
+47 40 33 00 11
henning.jansen@xboxlab.no
www.xboxlab.se

Mobidiag products are also available throughout Europe and the Middle East. Visit our Distributor page to learn more.

Real-time RT-PCR-based test enables fast, on demand and fully automated detection of early COVID-19 infections for rapid isolation and treatment guidance;

provides safety for users with a closed system;

easy to use with no need for highly trained personnel enabling decentralized testing.

Novodiag^® assay rapidly detects coronavirus and influenzas;
provides safety for users with a closed system;
easy to use with no need for highly trained personnel in high risk and hard to reach areas

Mobidiag Ltd. today announces that it has initiated development of a Novodiag® molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus (strain 2019-nCoV) and influenza viruses.

The assay is being developed in partnership with Autobio Diagnostics (Autobio), the market leading Chinese clinical diagnostics company, and Automobi Molecular Diagnostics (Automobi), the joint venture launched by Mobidiag and Autobio in May 2019.

The new Novodiag® test will operate using a rapid ‘sample-in, result-out’ system, allowing the rapid detection of both novel coronavirus and influenzas in around 30 minutes. In addition, the fully automated system protects laboratory staff and healthcare providers from possible contamination. The user-friendly nature of the system will mean that the Novodiag® platform can be delivered to and will be targeted for use in high risk and hard to reach areas without the need for highly trained personnel.

Tuomas Tenkanen, CEO of Mobidiag, said, “It is vital that molecular diagnostics solutions be utilized to fight back against novel coronavirus which has emerged as a significant threat to health across the world. Our new Novodiag® assay will uniquely offer rapid and fully automated molecular profiling to simultaneously detect novel coronavirus and common influenza strains and guide clinicians more quickly towards moving patients to efficient isolation measures and make better-informed treatment decisions, in situations where time is critical.”

“Our partner Autobio’s understanding of the developing situation in China, combined with our in-house expertise and flexibility of the Novodiag® platform, means we are well positioned to develop an effective diagnostic solution for such a global health emergency. Regulators around the world have recognized the need to expedite responses to the diagnosis and treatment of novel coronavirus and we intend to bring our test to market as rapidly as possible.”

Fu Guangyu, Director of Autobio and General Manager of Automobi, said, “To control the spread of 2019-nCov as soon as possible, a rapid, safe, and accurate etiological diagnosis technique is of paramount need. We are delighted that Mobidiag will use its expertise and know-how to develop an assay that can be used on the Novodiag® platform at this critical time. Autobio and Automobi will work closely with Mobidiag by sharing relevant technology, experience, resources and information in order to ensure we make a meaningful impact in the fight against the spread of 2019-nCov.”

The development of this new assay highlights the broad flexibility and applicability of the Novodiag® platform which combines real-time PCR and microarray technologies to allow for single to high-plex (100+) diagnostics, enabling future applications in areas such as infectious diseases, sepsis and oncology. It conducts comprehensive screening of multiple or single pathogens within approximately one hour, helping to deliver early treatments to patients and avoid the spread of infection.

About Autobio

Autobio Diagnostics Co., Ltd was established in 1998 and has become one of the largest and fastest growing clinical diagnostics companies in China. Autobio specialises in research & development, production, marketing and service of clinical diagnostic products, especially immunoassay, microbiology and biochemical products. Autobio provides comprehensive solutions for medical laboratories. Autobio was listed on Shanghai Stock Exchange on September 1st, 2016.

Autobio has more than 3700 staff and is headquartered in Zhengzhou, China. To learn more, visit www.autobio.com.cn

 

Agreements signed in Poland, Ukraine, Romania and Israel, with more in discussions.

ESPOO, Finland, October 29th, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has signed new exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with ALAB Ltd. for Poland and Ukraine, BIOgenetiX for Romania and Theranostica Ltd. for Israel.

Tuomas Tenkanen, CEO of Mobidiag, said “We are extremely pleased to have further expanded our commercial footprint into additional international territories. Our highly versatile and complementary Amplidiag® and Novodiag® diagnostic solutions continue to gain traction internationally. We are in ongoing discussions with several distribution partners in a range of international markets as customers look for fast, accurate and affordable diagnostic solutions to a wide range of infectious diseases.”

Gilda Cristea, Imports Manager of BIOgenetiX, comments “It is a great opportunity for BIOgenetiX to collaborate with Mobidiag in Romania. The control of infections and the identification of antibiotic resistant pathogens are critical in all clinical environments. Mobidiag offers a diverse range of products that are easy to use, have great diagnostic precision and are affordable. These products are very important for the general management of patients and hospitals and we see them offering a great opportunity for the future.”

Amnon Hezkaya CEO of Theranostica, continues “We are really excited to start this partnership between Theranostica and Mobidiag. Mobidiag with its Novodiag® solution has the potential to be transformational for Israeli clinical laboratory customers as an affordable, fast sample to result system, which can test multiple targets at once.”

Contacts
Johanna Sarapää, Marketing Communications
+358 10 2054 771
marketing@mobidiag.com

Consilium Strategic Communications
Chris Gardner, Matthew Neal, Chris Welsh
T: +44 (0)203 709 5700
mobidiag@consilium-comms.com

Notes to editors

About Mobidiag Ltd.
Mobidiag is a revenue generating, fast growing molecular diagnostics company with complementary platform technologies that can meet the differing diagnostic needs for customers in multiple healthcare settings. Initially designed for ease of use and adapatability for large scale manufacturing, Mobidiag’s Amplidiag® and Novodiag® platforms provide a combination of high quality and affordability, allowing for widespread applicability for both mass screening and highly specific syndromic testing in multiple indications. The Company’s highly versatile product offering enables the broad application of molecular diagnostics to address the global challenge of antimicrobial resistance and other unmet diagnostic needs. Mobidiag’s intial focus has been on gastrointestinal diseases and superbugs, through direct sales and distributors, and is rapidly building a leading position in European markets.

Mobidiag has more than 100 staff and is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com

About ALAB Ltd.

ALAB Ltd. based in Warsaw, Poland is a specialized company operating in the laboratory market in Poland and Ukraine. ALAB Ltd. is a member of ALAB GROUP including ALAB LABORATORIA – a key market player in routine and specialized diagnostics and ALAB PLUS – histopathology laboratory service. For 25 years ALAB Ltd. has been conducting commercial and service activities for public and private institutions. Its specialty is the comprehensive equipping of laboratory rooms in biotechnology, molecular biology, physico-chemical, microbiology and diagnostics.

About BIOgenetiX

BIOgenetiX is a distribution company for medical products in Romania. The company provides products and technical support for laboratories performing molecular biology diagnostic tests. BIOgenetiX addresses both state owned and private clinics, laboratories and hospitals. The company was established in 2009 and at the moment it is one of the most important Romanian companies in the field of medical products distribution. BIOgenetiX has a special program in the area of infections control and prevention. The company is focused on providing customers with more advanced technologies for molecular diagnostics and resistance genes identification.

Theranostica Ltd.

Theranostica Ltd., established in 2010 is a leading Israeli distributor for innovative clinical diagnostics solutions from the United States, Europe and Asia. In the past nine years Theranostica has been succesful in bringing to the Israeli health system dozens of new technologies which helped to provide better medicine.

Access full press release in English

Agreement signed for South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya, Uganda

ESPOO, Finland, July 1^st, 2019 – Mobidiag Ltd. today announces that it has signed an exclusive agreement with Pro Med Diagnostics for the distribution of its Amplidiag® and Novodiag® products in African countries including South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Malawi, Kenya and Uganda.

Tuomas Tenkanen, CEO of Mobidiag, said “We are excited to further expand our commercial footprint into Africa, which represents a fast growing market for diagnostic products with enormous growth potential. We are focused on continuing to develop our distributor network as part of our strategy to make our IVD tests and instruments accessible to customers in centralized and decentralized settings around the world. With a strong background in molecular diagnostics and an extensive customer network, Pro Med Diagnostics is the ideal partner to distribute our products throughout Africa.”

Pro Med Diagnostics founders Neil and Anne Barker, said “We are looking forward to expanding our current product offering by including the novel Mobidiag platform and tests – the ease of use and proven reliability of this platform offers our customers the option of expanding test offerings with minimal fuss and disruption to their current testing algorithms. Fast time to result is crucial in ensuring better patient outcomes. We are proud to be partnering with this strongly positioned product brand, which will further cement our position within the current medical diagnostic market.”

Contacts

Mobidiag

Dorothee Allard

T: +33 (0)1 55 25 17 13

marketing@mobidiag.com

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Chris Welsh

T: +44 (0)203 709 5700

mobidiag@consilium-comms.com

Pro Med Diagnostics

Anne Barker

anne.barker@pro-med.co.za

Notes to editors

About Mobidiag Ltd

Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.

Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com.

About Pro Med Diagnostics (Pty) Ltd.

Pro Med Diagnostics is a Medical Diagnostic company specialising in the supply of laboratory based diagnostic products in the field of Fungal and Infectious diseases.

The founders of Pro Med Diagnostics, Neil and Anne Barker, have worked within the Medical Diagnostic field for all of their professional careers bringing a wealth of knowledge and experience to the organisation. Pro Med Diagnostics focuses on delivering an optimal level of customer support from the supply of quality products and service delivery.

Access full pdf version in English.

Agreements signed in Greece, Latvia, Lithuania and Kuwait, with more in discussions

Mobidiag Ltd.announced today that it has signed multiple exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with Helix2 for Greece and Interlab INTERAUTOMATIKA UAB for Latvia and Lithuania. Mobidiag has also signed its first agreement in the Middle East with Ibn Rushd Medical & Scientific Equipment Co. for the distribution of Novodiag® in Kuwait. The agreements are effective immediately and initially in place for a period of two years.

Tuomas Tenkanen, CEO of Mobidiag, said “We are delighted to have extended our commercial footprint into new international territories including our first agreement in the Middle East. Mobidiag continues to see demand grow for the Amplidiag® and Novodiag® solutions and we are in discussions with several distribution partners in a range of international markets, as customers look for comprehensive diagnostic solutions to a wide range of infectious diseases in both centralised and decentralised laboratories.”

 

Contacts

Mobidiag
Dorothee Allard, Marketing Communications Manager
+33 1 55 25 17 13
marketing@mobidiag.com

Consilium Strategic Communications
Chris Gardner, Matthew Neal, Chris Welsh
T: +44 (0)203 709 5700
mobidiag@consilium-comms.com

 

Read full press release: in English, in French

CE-IVD marking of Novodiag^® CarbaR+, the 3rd molecular test on the automated system Novodiag^®, for detection of the main Carbapenemase-Producing Enterobacteriaceae (CPE) and colistin resistance markers in one single test.

ESPOO, Finland, January 7^th, 2019 – Mobidiag Ltd. today announces the CE-IVD marking of Novodiag® CarbaR+. Novodiag® CarbaR+ is a single molecular test allowing fully automated detection of Carbapenemase-Producing Enterobacteriaceae (CPE), and associated resistance markers. CPE are bacteria that are resistant to carbapenem class of antibiotics. In addition, Novodiag® CarbaR+ identifies a plasmid-mediated resistance to colistin. Colistin is considered the drug of last resort for many infections.

Novodiag® CarbaR+ combines multiplex qPCR and microarray testing in a single product allowing cost-effective and fast analysis of the most common CPE and colistin resistance markers. These bacteria may cause multiple antibiotics to perform inefficiently, which in turn can lead to serious infections, particularly in healthcare settings. The test is designed to run on-demand using the automated Novodiag® system, producing results in 80 minutes with less than five minutes hands-on time by an operator.

With two multiplex tests already available for screening antibiotic resistance (Amplidiag® CarbaR+VRE and Amplidiag® CarbaR+MCR), the new on demand Novodiag® CarbaR+ test will enable rapid patient screening for multidrug resistant organisms, helping to prevent their spread in a hospital environment, and enabling physicians to guide patient treatment accordingly.

Tuomas Tenkanen, CEO of Mobidiag, said, “Antimicrobial resistance is one of the most significant challenges to global health. Mobidiag is contributing to the fight against “super bacteria” by developing innovative diagnostic tools. Novodiag® CarbaR+ is our third test on the Novodiag® system and strengthens our offering in the fight against antibiotic resistance. Together with our Amplidiag® and Novodiag® tests, we offer comprehensive diagnostic solutions to a wide range of infectious diseases in both centralised and decentralised laboratories regardless of their size and patient volumes”.

The Novodiag® CarbaR+ test is now available directly through Mobidiag and local distributors. For more information, visit our product page.

About Novodiag^® CarbaR+ (CE-IVD)

Novodiag® CarbaR+ is combining multiplex qPCR and microarray in one single test allowing cost-effective and fast analysis of the most common carbapenemase-producing enterobacteriaceae and colistin resistance markers. The complete panel includes the detection of the following genes: KPC, NDM, VIM, IMP, OXA-23, OXA-24, OXA-48/181, OXA-51, OXA-58 and MCR-1. These may cause multiple antibiotics to perform inefficiently, which in turn can lead to serious infections, particularly in healthcare settings. This test is run on the on demand automated Novodiag® system with results in 80 minutes and less than 5 minutes hands-on time directly from pure culture and rectal swabs.

 

Contacts

Dorothee Allard, Marketing Communications Manager

+33 1 55 25 17 13

marketing@mobidiag.com

 

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Chris Welsh

T: +44 (0)203 709 5700

mobidiag@consilium-comms.com

 

WG Partners

Andrew Craig, Partner

+44 203 705 9320

andrew@wgpartners.co.uk

 

Read full press release: English, Finnish, French

New molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples.
Espoo, Finland, April 17^th, 2018 – Mobidiag today announced the launch of Novodiag^® Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Compatible with the fully automated Novodiag® system launched at the end of 2017, this new disposable cartridge allows direct analysis of a patient sample and delivers comprehensive results in about an hour, compared to days with currently used culture methods.

 

“The new Novodiag Bacterial GE+ cartridge can identify dozens of targets, including the majority of bacteria causing diarrhea. Thanks to its simplified and optimized workflow, our fully automated Novodiag solution can support early decision making prior to any treatment delivery and improve patient care by managing infections accordingly” explains Tuomas Tenkanen. “We are very proud to now offer the first syndromic test compatible with our Novodiag system. Our ambition is to make accessible one of the most relevant range of test panels. We are currently working on extending our product line and address among others the detection of antibiotic resistances to improve the correct use of antibiotics”.

 

Novodiag® Bacterial GE+ test is now available directly through Mobidiag and local distributors. For more information, visit our product page.

 

About Novodiag^® (CE-IVD)

The Novodiag solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour. Combining qPCR and microarray technologies, Novodiag offers an all in one solution for on-demand targeted and syndromic testing.

This molecular diagnostic solution offers an easy to use and cost-efficient method, with very limited hands-on-time and without the need for much technical expertise. Novodiag is suitable for all test volumes and on demand testing for clinical laboratories.

Learn more about Novodiag.

Do not hesitate to contact us for more information.

 

See full press release in English.

See full press release in French.